Double-blind cross-over study of levamisole as immunoprophylaxis for recurrent herpes progenitalis.
A double-blind cross-over study of the immunoprophylactic influence of levamisole was undertaken in a study of forty patients with chronic, recurrent herpes progenitalis. Clinical records failed to show significant reduction in the frequency or severity of attacks in levamisole-treated patients when compared with placebo-treated control patients. At evaluation six months after levamisole administration, there was no essential alteration in the course of the disease in the initial treatment group.